BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 32727215)

  • 1. Histone deacetylases in modulating cardiac disease and their clinical translational and therapeutic implications.
    Wang Z; Zhao YT; Zhao TC
    Exp Biol Med (Maywood); 2021 Jan; 246(2):213-225. PubMed ID: 32727215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The important role of histone deacetylases in modulating vascular physiology and arteriosclerosis.
    Zhao TC; Wang Z; Zhao TY
    Atherosclerosis; 2020 Jun; 303():36-42. PubMed ID: 32535412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nonepigenetic role for small molecule histone deacetylase inhibitors in the regulation of cardiac function.
    Romanick SS; Ferguson BS
    Future Med Chem; 2019 Jun; 11(11):1345-1356. PubMed ID: 31161804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.
    Kee HJ; Kook H
    J Biomed Biotechnol; 2011; 2011():928326. PubMed ID: 21151616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting histone deacetylases for heart diseases.
    Jin G; Wang K; Zhao Y; Yuan S; He Z; Zhang J
    Bioorg Chem; 2023 Sep; 138():106601. PubMed ID: 37224740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases.
    Eom GH; Kook H
    Pharmacol Ther; 2014 Aug; 143(2):168-80. PubMed ID: 24594235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone Deacetylases in Kidney Physiology and Acute Kidney Injury.
    Hyndman KA
    Semin Nephrol; 2020 Mar; 40(2):138-147. PubMed ID: 32303277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer.
    Parbin S; Kar S; Shilpi A; Sengupta D; Deb M; Rath SK; Patra SK
    J Histochem Cytochem; 2014 Jan; 62(1):11-33. PubMed ID: 24051359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes.
    Ooi JY; Tuano NK; Rafehi H; Gao XM; Ziemann M; Du XJ; El-Osta A
    Epigenetics; 2015; 10(5):418-30. PubMed ID: 25941940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase (HDACs) inhibitors: Clinical applications.
    Shanmukha KD; Paluvai H; Lomada SK; Gokara M; Kalangi SK
    Prog Mol Biol Transl Sci; 2023; 198():119-152. PubMed ID: 37225317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention.
    Ganai SA
    Curr Drug Targets; 2018; 19(6):593-601. PubMed ID: 27231104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis.
    Citraro R; Leo A; Santoro M; D'agostino G; Constanti A; Russo E
    Curr Pharm Des; 2017; 23(37):5546-5562. PubMed ID: 29076408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innovative Strategies for Selective Inhibition of Histone Deacetylases.
    Maolanon AR; Madsen AS; Olsen CA
    Cell Chem Biol; 2016 Jul; 23(7):759-768. PubMed ID: 27447046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emerging roles of HDACs and their therapeutic implications in cancer.
    Hai R; Yang D; Zheng F; Wang W; Han X; Bode AM; Luo X
    Eur J Pharmacol; 2022 Sep; 931():175216. PubMed ID: 35988787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of dietary histone deacetylases (HDACs) inhibitors in health and disease.
    Bassett SA; Barnett MP
    Nutrients; 2014 Oct; 6(10):4273-301. PubMed ID: 25322459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromatin modifications remodel cardiac gene expression.
    Mathiyalagan P; Keating ST; Du XJ; El-Osta A
    Cardiovasc Res; 2014 Jul; 103(1):7-16. PubMed ID: 24812277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors.
    Bush EW; McKinsey TA
    Circ Res; 2010 Feb; 106(2):272-84. PubMed ID: 20133912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylases as therapeutic targets--from cancer to cardiac disease.
    Abend A; Kehat I
    Pharmacol Ther; 2015 Mar; 147():55-62. PubMed ID: 25444758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential of targeting epigenetic regulators for the treatment of fibrotic cardiac diseases.
    Schuetze KB; Koch KA; McKinsey TA
    Future Med Chem; 2016 Sep; 8(13):1533-6. PubMed ID: 27556930
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.